Biophytis postpones the publication of its 2025 annual accounts

Biophytis SA, a biotechnology company specializing in the development of treatments for age-related diseases, has announced the postponement of the publication of its annual financial statements for the 2025 fiscal year. This postponement, initially scheduled for April 30, 2026, is due to a €2.015 million refinancing operation. The company's efforts have been focused on discussions and negotiations related to this refinancing.

Biophytis justifies this delay by the need for additional time to finalize its closing procedures and their review by the auditors. The company hopes to publish its financial statements by the end of May 2026.